PDCD1 and breast cancer: The phase II new-onset refractory status epilepticus (NORSE) trial compared erdafitinib alone and in combination with cetrelimab, a PD-1 monoclonal antibody in patients with metastatic BC not previously treated with cisplatin-based chemotherapy.